For the present study, the following data were re- residuals were used to test the proportionality assumption 154 with 95% confidence intervals (CI). All hazard ratios (HR) 155 estimated in survival analysis were based on analysis of 156 dichotomous variables, using the 50th percentile for 157 continuous variables, and absence/presence of a feature 158 for categorical variables. The same models were also 159 assessed using the continuous baseline variables, and the 160 strength of association expressed as Z values (the ratio of 161 the HR and SE). The International System of Units is 162 used throughout the text. Unless otherwise indicated, 163 two-tailed P values of < 0.05 were considered signifi-164 cant. Statistical analyses were performed using STATA 165 14 (College Station, Texas, USA).
Results

167
All enrolled patients completed the follow-up unless 168 pre-empted by death-except three patients for whom 169 survival time was censored before 17 years (two withdrew 170 consent and one moved overseas). Among the589 patients 171 who were discharged alive, 18patients had previously 172 diagnosed malignancy at the time of enrollment and were
173
excluded from the present analysis. Ninety-nine patients 174 developed the disease during the follow-up (Fig. 1) . Table   T1 1 175 presents the patients' baseline clinical characteristics ac-176 cording to the development of neoplasia during follow-up.
177
The two groups did not differ in age at enrollment, history Plasma HDL levels did not differ between groups.
185
The rate of using lipid-lowering treatment throughout 186 follow-up did not significantly differ between non-187 neoplastic patients (47%) and neoplastic patients 188 (43%)(chi 2 = 2.9, p = 0.23).
189
Comparing patients who developed neoplasia to those 190 who did not, there were no differences in the rate of 
194
The incidence rate of new malignancy throughout 195 follow-up after ACS was approximately18 cases/1000 196 person-years. Unexpectedly, this incidence rate was 197 markedly higher (23 cases/1000 person-years)among 198 patients with baseline TC ≤ median value of 208 mg/dL, 199 and the estimated rate ratio was significantly below 1 200 (Table   T2 2). A similar rate ratio was observed for LDL. In 201 contrast, the rate ratio was closer to 1and non-significant 202 for HDL and TG. Figure   F2 2 presents the cumulative incidence of malignancy 224 onset and neoplastic death throughout the follow-up in 225 patients with plasma TC and LDL values of > or ≤ median 226 values, revealing significant differences between these 227 groups (Table 2 ). There were no significant differences 228 relative to HDL and TG (Fig.   F3 3).
229
Univariable Cox survival analysis demonstrated that the 230 hazard of malignancy onset and neoplastic mortality 231 throughout follow-up after ACS were higher among 232 patients with baseline TC or LDL values ≤ median values 233 (Table   T3 3). The proportional hazards assumption was 234 verified for all variables concerning plasma lipid levels 235 (p ≥ 0.10).
236
The higher hazard remained significant even after 237 accounting for clinical confounders in the fully adjusted 238 models and the parsimonious models (Table 3) . Fully 
312
The relationship between plasma cholesterol con-313 centration and mortality is complex. Although plasma 314 concentration is positively correlated with CAD-related 315 mortality, it shows a negative relationship with death 316 from cancer. These two relationships could reflect causal 317 mechanisms that are reversible by changes in plasma TC 318 concentration. In this scenario, the benefits of lipid 319 reduction for heart disease might be partly offset by 320 increased cancer-related mortality [31] .
321
In concordance with the medical knowledge, we found 322 association between malignancy risk and other impor- 
